Corxel to Go Public in US via SPAC Deal
Obesity drug developer Corxel Pharmaceuticals announced it will go public in the United States through a merger with Amanat Acquisition Corp. The transaction is expected to provide roughly $377 million in funding to advance its pipeline of oral metabolic therapies.
Xurve View
Insights:
Xurve View
Obesity drug developer Corxel Pharmaceuticals will go public in the United States through a merger with Amanat Acquisition Corp, securing $377M in total proceeds. The deal highlights investor demand for weight-loss treatments currently dominated by Novo Nordisk A/S-B and Eli Lilly & Co . Corxel's public market debut will fund late-stage trials for its oral cardiometabolic drug pipeline.
